Pub Date : 2025-04-15eCollection Date: 2025-01-01DOI: 10.1155/ogi/5582127
Kevin Dominique Tjandraprawira, Edwin Armawan, Muhammad Alamsyah Aziz, Tono Djuwantono
Introduction: Female technology or 'femtech' is the availability of mobile applications (apps) to monitor specific aspects of women's health. It touts the benefits of technology to empower women with regards to their health, while also allowing close collaboration between patients and physicians. Endometriosis-specific apps is a channel by which female patients discover their endometriosis diagnosis. However, there is currently a paucity of high-quality and evidence-based endometriosis apps. This study assessed the current state and overall quality of such apps. Materials and Methods: This retrospective study assessed patient-centred endometriosis apps on the Apple iTunes Store, in January 2023, excluding certain categories such as conference guidance, gaming, private healthcare, and clinical trial apps. The key term "endometriosis" was used. All patient-centred apps were included. The apps were assessed using the APPLICATIONS scoring system, considering objective factors like pricing, subscriptions, literature references, in-app purchases, connectivity, advertisements, search fields, interoperability, and subjective elements such as navigation ease and presentation. The maximum score is 16 and all applications were assessed in English. Results: Out of the initial 22 apps, 12 (54.5%) were excluded, leaving 10 (45.5%) for analysis. Most apps lacked comprehensiveness, but two apps (LUNA-endometriosis and Frendo) stood out with high scores. These apps incorporated certified scoring systems, provided recommendations for tests and follow-up visits, and offered evidence-based literature on endometriosis. The remaining apps scored poorly, focusing on alternative treatments, healthy diets, or functioning solely as symptom diaries, with limited information on diagnosis and management. Only a few apps allowed booking follow-up visits, and most lacked the capability to export patient-specific data. Few apps measured the likelihood of endometriosis whilst others relied on previous diagnoses. The majority of apps were free, whilst in-app purchases centred around alternative treatments. Overall, the apps were user-friendly, featuring vibrant colours and intuitive interfaces. Conclusions: Only two patient-centred endometriosis apps scored highly in the APPLICATIONS scoring system as they were high-quality, evidence-based and incorporated valid medical recommendations. Other applications scored low as their recommendations lacked quality scientific evidence.
{"title":"A Study on the Quality of Patient-Centred Endometriosis Mobile Applications: Analysis and Future Prospects.","authors":"Kevin Dominique Tjandraprawira, Edwin Armawan, Muhammad Alamsyah Aziz, Tono Djuwantono","doi":"10.1155/ogi/5582127","DOIUrl":"https://doi.org/10.1155/ogi/5582127","url":null,"abstract":"<p><p><b>Introduction:</b> Female technology or 'femtech' is the availability of mobile applications (apps) to monitor specific aspects of women's health. It touts the benefits of technology to empower women with regards to their health, while also allowing close collaboration between patients and physicians. Endometriosis-specific apps is a channel by which female patients discover their endometriosis diagnosis. However, there is currently a paucity of high-quality and evidence-based endometriosis apps. This study assessed the current state and overall quality of such apps. <b>Materials and Methods:</b> This retrospective study assessed patient-centred endometriosis apps on the Apple iTunes Store, in January 2023, excluding certain categories such as conference guidance, gaming, private healthcare, and clinical trial apps. The key term \"endometriosis\" was used. All patient-centred apps were included. The apps were assessed using the APPLICATIONS scoring system, considering objective factors like pricing, subscriptions, literature references, in-app purchases, connectivity, advertisements, search fields, interoperability, and subjective elements such as navigation ease and presentation. The maximum score is 16 and all applications were assessed in English. <b>Results:</b> Out of the initial 22 apps, 12 (54.5%) were excluded, leaving 10 (45.5%) for analysis. Most apps lacked comprehensiveness, but two apps (LUNA-endometriosis and Frendo) stood out with high scores. These apps incorporated certified scoring systems, provided recommendations for tests and follow-up visits, and offered evidence-based literature on endometriosis. The remaining apps scored poorly, focusing on alternative treatments, healthy diets, or functioning solely as symptom diaries, with limited information on diagnosis and management. Only a few apps allowed booking follow-up visits, and most lacked the capability to export patient-specific data. Few apps measured the likelihood of endometriosis whilst others relied on previous diagnoses. The majority of apps were free, whilst in-app purchases centred around alternative treatments. Overall, the apps were user-friendly, featuring vibrant colours and intuitive interfaces. <b>Conclusions:</b> Only two patient-centred endometriosis apps scored highly in the APPLICATIONS scoring system as they were high-quality, evidence-based and incorporated valid medical recommendations. Other applications scored low as their recommendations lacked quality scientific evidence.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"5582127"},"PeriodicalIF":1.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-25eCollection Date: 2025-01-01DOI: 10.1155/ogi/1771858
Samyama Sagare Venkatesh, Malathi T, Manasa A S Gowda
Purpose: This study aimed to evaluate the effect of COVID-19 infection and vaccination on all the menstrual cycle parameters in the women of reproductive age group, 18-45 years, at a tertiary care hospital. Methods: A single-center, descriptive cross-sectional study was done from January 2, 2023, to June 24, 2023. Sampling was nonprobabilistic and purposeful. Participants were recruited via calls, in-person interviews, and online surveys. A total of 931 participants were recruited, of which 141 participants were eligible for the study. Descriptive statistics were performed for all variables. Pearson's chi-square test was done to compare categorical variables among different groups, and the Wilcoxon matched pair signed-rank test was done to compare the menstrual cycle patterns before and after COVID-19 infection and vaccination. Simple linear regression and multiple linear regression analysis were done wherever necessary. p < 0.05 was considered statistically significant. Results: A total of 931 participants were recruited, of which 141 participants were eligible for the study. The median age was 29 years. Those who reported menstrual abnormalities were mainly of the age group 18-27 (n = 62, 44.0%), resided in an urban locality (n = 123, 87.2%), and were employed (full-time/part-time) (n = 57, 40.4%). Of the 42 participants with menstrual changes, 27 (64.3%) participants experienced changes post-COVID-19 infection before their first vaccination dose and 15 (35.7%) after the first vaccination dose. In this group, 15 (35.7%) continue to experience abnormalities in their cycles. Analysis showed that participants having severe COVID-19 symptoms were more likely to have an earlier onset of menstrual abnormalities (beta = -2.072, p=0.040). Participants with an above-normal BMI were more likely to have increased pain/cramps during menses (beta = 0.236, p=0.0.013). Participants who were students/employed (beta = -0.365, p=0.001) with an above-normal BMI (beta = 0.182, p=0.024) were more likely to experience increased mood swings/tension/irritability. On comparing the onset and duration of menstrual abnormalities in the post-COVID-19 infection and postvaccination groups, it was found that the latter group had a late-onset and short-term effect, while the former group had an early-onset and long-term effect on menses. Conclusion: Our study shows that there is evidence of the onset of menstrual irregularities following COVID-19 infection and vaccination. The study revealed COVID-19 infection and vaccination influence menstrual cycles, the former posing a higher risk, but their effects on menstruation independent of one another are to be studied further.
{"title":"A Cross-Sectional Study on Post-COVID-19 Menstrual Abnormalities in Women of Reproductive Age Group at a Tertiary Care Hospital.","authors":"Samyama Sagare Venkatesh, Malathi T, Manasa A S Gowda","doi":"10.1155/ogi/1771858","DOIUrl":"10.1155/ogi/1771858","url":null,"abstract":"<p><p><b>Purpose:</b> This study aimed to evaluate the effect of COVID-19 infection and vaccination on all the menstrual cycle parameters in the women of reproductive age group, 18-45 years, at a tertiary care hospital. <b>Methods:</b> A single-center, descriptive cross-sectional study was done from January 2, 2023, to June 24, 2023. Sampling was nonprobabilistic and purposeful. Participants were recruited via calls, in-person interviews, and online surveys. A total of 931 participants were recruited, of which 141 participants were eligible for the study. Descriptive statistics were performed for all variables. Pearson's chi-square test was done to compare categorical variables among different groups, and the Wilcoxon matched pair signed-rank test was done to compare the menstrual cycle patterns before and after COVID-19 infection and vaccination. Simple linear regression and multiple linear regression analysis were done wherever necessary. <i>p</i> < 0.05 was considered statistically significant. <b>Results:</b> A total of 931 participants were recruited, of which 141 participants were eligible for the study. The median age was 29 years. Those who reported menstrual abnormalities were mainly of the age group 18-27 (<i>n</i> = 62, 44.0%), resided in an urban locality (<i>n</i> = 123, 87.2%), and were employed (full-time/part-time) (<i>n</i> = 57, 40.4%). Of the 42 participants with menstrual changes, 27 (64.3%) participants experienced changes post-COVID-19 infection before their first vaccination dose and 15 (35.7%) after the first vaccination dose. In this group, 15 (35.7%) continue to experience abnormalities in their cycles. Analysis showed that participants having severe COVID-19 symptoms were more likely to have an earlier onset of menstrual abnormalities (beta = -2.072, <i>p</i>=0.040). Participants with an above-normal BMI were more likely to have increased pain/cramps during menses (beta = 0.236, <i>p</i>=0.0.013). Participants who were students/employed (beta = -0.365, <i>p</i>=0.001) with an above-normal BMI (beta = 0.182, <i>p</i>=0.024) were more likely to experience increased mood swings/tension/irritability. On comparing the onset and duration of menstrual abnormalities in the post-COVID-19 infection and postvaccination groups, it was found that the latter group had a late-onset and short-term effect, while the former group had an early-onset and long-term effect on menses. <b>Conclusion:</b> Our study shows that there is evidence of the onset of menstrual irregularities following COVID-19 infection and vaccination. The study revealed COVID-19 infection and vaccination influence menstrual cycles, the former posing a higher risk, but their effects on menstruation independent of one another are to be studied further.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"1771858"},"PeriodicalIF":1.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-24eCollection Date: 2025-01-01DOI: 10.1155/ogi/4043963
Anastasia Salame, Elias M Dahdouh, Mokhamad Zhaffal, Rania Aljafari, Arya Muraleekrishnan, Aparna Bajpai, Shabin Kainoth, Leyla Depret Bixio, Michael Fakih
Background: "No result" after PGT-A is a rare observation. Factors suspected to cause inconclusive diagnoses include poor embryo quality, day of biopsy, biopsy technique, and technical amplification failure due to diluted DNA material. This study aimed to highlight the predisposing factors that could lead to a "no result" observation after PGT-A. Results: This is a retrospective cohort study involving 177 patients and 1335 blastocysts, 1242 of which comprised the control (result) group and 93 comprised the study (no result) group. The predisposing factors studied were the number of blastocysts available for biopsy, the day of biopsy, the grade of the embryo, the degree of expansion of the blastocyst, and the grade of the trophectoderm on biopsy day. The rate of "no result" embryos did not depend on the degree of expansion of the embryo, the trophectoderm quality, the day of biopsy, or embryo grade (p=0.139, 0.34, 0.332, and 0.272, respectively). Regression analysis showed that the studied embryo characteristics were not significant predisposing factors. However, having more blastocysts to biopsy per patient was found to be a significant predictor of "no result" embryos. Conclusion: No clear embryo-related risk factors could be elucidated; however, the biopsy procedure and sample cellularity seem to be crucial components. In addition, having more embryos per patient to biopsy at a given time might increase the risk of having inconclusive biopsy results.
{"title":"Embryos With \"No Result\" After PGT-A: A Retrospective Analysis of Causative Factors.","authors":"Anastasia Salame, Elias M Dahdouh, Mokhamad Zhaffal, Rania Aljafari, Arya Muraleekrishnan, Aparna Bajpai, Shabin Kainoth, Leyla Depret Bixio, Michael Fakih","doi":"10.1155/ogi/4043963","DOIUrl":"10.1155/ogi/4043963","url":null,"abstract":"<p><p><b>Background:</b> \"No result\" after PGT-A is a rare observation. Factors suspected to cause inconclusive diagnoses include poor embryo quality, day of biopsy, biopsy technique, and technical amplification failure due to diluted DNA material. This study aimed to highlight the predisposing factors that could lead to a \"no result\" observation after PGT-A. <b>Results:</b> This is a retrospective cohort study involving 177 patients and 1335 blastocysts, 1242 of which comprised the control (result) group and 93 comprised the study (no result) group. The predisposing factors studied were the number of blastocysts available for biopsy, the day of biopsy, the grade of the embryo, the degree of expansion of the blastocyst, and the grade of the trophectoderm on biopsy day. The rate of \"no result\" embryos did not depend on the degree of expansion of the embryo, the trophectoderm quality, the day of biopsy, or embryo grade (<i>p</i>=0.139, 0.34, 0.332, and 0.272, respectively). Regression analysis showed that the studied embryo characteristics were not significant predisposing factors. However, having more blastocysts to biopsy per patient was found to be a significant predictor of \"no result\" embryos. <b>Conclusion:</b> No clear embryo-related risk factors could be elucidated; however, the biopsy procedure and sample cellularity seem to be crucial components. In addition, having more embryos per patient to biopsy at a given time might increase the risk of having inconclusive biopsy results.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"4043963"},"PeriodicalIF":1.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-24eCollection Date: 2025-01-01DOI: 10.1155/ogi/5578247
Shitong Zhan, Feng Chen, Lijuan Huang, Lin Chen, Haoyi Jia, Shaofei Ma, Min Tang, Chongzhi Zhou, Yanmin Chen, Ye Yang
<p><p><b>Backgrouds:</b> Whether homologous recombination repair (HRR) mutation has a differential effect on the prognosis has not been confirmed by current studies. The purpose of this study was to explore the clinical importance, prognostic value, and frequency of pathogenic changes in HRR genes in patients with ovarian cancer (OC). <b>Methods:</b> We analyze information including HRR mutation and clinical prognosis of OC patients both in our cohort and in the TCGA-OV database. Blood and/or tumor samples from 98 women admitted to Shanghai General Hospital between January 2021 and May 2024, and DNA sequencing was performed on these samples for all patients included in this retrospective study. Testing was performed for HRR mutations, including germline BRCA1/2 mutations, and defects in HRR were defined as detrimental mutations within relevant genes. Comprehensive medical records were gathered for all patients, with a follow-up period recorded for 74 of them. <b>Results:</b> HRR pathway genes, including BRCA1/2, CDK12, RAD54L, RAD51, ATM, MRE11, and BRIP2, are highly expressed in FIGO Stages I-II OCs among 482 patients in the TCGA-OV database, and 95.06% samples presented mutations. The alignment diagram analyzed by logistic and Cox regression was derived to investigate HRR genes on overall survival (OS < 763 days) of OC patients. A total of 98 patients were enrolled in our study, with 70 harboring HRR mutations (HRRmt) and 28 having the HRR wild-type (HRRwt). The predominant pathological type across all four patient groups was high-grade serous adenocarcinoma, with similar prevalence in HRRmt (84.30%) versus HRRwt (75%, <i>p</i>=0.360) and BRCAmt (94.20%) versus BRCAwt (74.60%, <i>p</i>=0.151) groups. Survival prediction data were collected from 74 patients, and the HRRmt group (<i>n</i> = 50) exhibited a numerically longer PFS compared to the HRRwt group (<i>n</i> = 24), with 23 months versus 17 months, respectively. A significant disparity was noted in the percentage of patients administered PARPi medication between the HRRmt and HRRwt groups (58.00% vs. 20.20%; <i>p</i>=0.003). Patients in both the HRRmt group (<i>p</i>=0.049) and the BRCAwt group (<i>p</i>=0.046) receiving PARPi treatment have extended PFS. Significant differences were identified between HRRmt and HRRwt groups in the size of the initial debulking surgery achieving R0 status (<i>p</i>=0.005), low CA125 levels (< 1000 U/mL) at diagnosis (<i>p</i>=0.015), and the use of PARP inhibitors (PARPi) (<i>p</i>=0.024) and antiangiogenic drugs (<i>p</i> < 0.001). For patients with HRR mutations, the use of PARPi significantly impacted PFS (<i>p</i>=0.049), and achieving R0 status (<i>p</i>=0.005) significantly influenced PFS. <b>Conclusions:</b> This study indicates that mutations in the HRR gene possess significant potential as a prognostic marker in OC. Our aim was to comprehensively explore how HRR gene mutations, including but not limited to BRCA, might influence the clinical course
{"title":"The Clinical Pathological Characteristics and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Ovarian Cancer Patients: A Prospective Cohort Study.","authors":"Shitong Zhan, Feng Chen, Lijuan Huang, Lin Chen, Haoyi Jia, Shaofei Ma, Min Tang, Chongzhi Zhou, Yanmin Chen, Ye Yang","doi":"10.1155/ogi/5578247","DOIUrl":"10.1155/ogi/5578247","url":null,"abstract":"<p><p><b>Backgrouds:</b> Whether homologous recombination repair (HRR) mutation has a differential effect on the prognosis has not been confirmed by current studies. The purpose of this study was to explore the clinical importance, prognostic value, and frequency of pathogenic changes in HRR genes in patients with ovarian cancer (OC). <b>Methods:</b> We analyze information including HRR mutation and clinical prognosis of OC patients both in our cohort and in the TCGA-OV database. Blood and/or tumor samples from 98 women admitted to Shanghai General Hospital between January 2021 and May 2024, and DNA sequencing was performed on these samples for all patients included in this retrospective study. Testing was performed for HRR mutations, including germline BRCA1/2 mutations, and defects in HRR were defined as detrimental mutations within relevant genes. Comprehensive medical records were gathered for all patients, with a follow-up period recorded for 74 of them. <b>Results:</b> HRR pathway genes, including BRCA1/2, CDK12, RAD54L, RAD51, ATM, MRE11, and BRIP2, are highly expressed in FIGO Stages I-II OCs among 482 patients in the TCGA-OV database, and 95.06% samples presented mutations. The alignment diagram analyzed by logistic and Cox regression was derived to investigate HRR genes on overall survival (OS < 763 days) of OC patients. A total of 98 patients were enrolled in our study, with 70 harboring HRR mutations (HRRmt) and 28 having the HRR wild-type (HRRwt). The predominant pathological type across all four patient groups was high-grade serous adenocarcinoma, with similar prevalence in HRRmt (84.30%) versus HRRwt (75%, <i>p</i>=0.360) and BRCAmt (94.20%) versus BRCAwt (74.60%, <i>p</i>=0.151) groups. Survival prediction data were collected from 74 patients, and the HRRmt group (<i>n</i> = 50) exhibited a numerically longer PFS compared to the HRRwt group (<i>n</i> = 24), with 23 months versus 17 months, respectively. A significant disparity was noted in the percentage of patients administered PARPi medication between the HRRmt and HRRwt groups (58.00% vs. 20.20%; <i>p</i>=0.003). Patients in both the HRRmt group (<i>p</i>=0.049) and the BRCAwt group (<i>p</i>=0.046) receiving PARPi treatment have extended PFS. Significant differences were identified between HRRmt and HRRwt groups in the size of the initial debulking surgery achieving R0 status (<i>p</i>=0.005), low CA125 levels (< 1000 U/mL) at diagnosis (<i>p</i>=0.015), and the use of PARP inhibitors (PARPi) (<i>p</i>=0.024) and antiangiogenic drugs (<i>p</i> < 0.001). For patients with HRR mutations, the use of PARPi significantly impacted PFS (<i>p</i>=0.049), and achieving R0 status (<i>p</i>=0.005) significantly influenced PFS. <b>Conclusions:</b> This study indicates that mutations in the HRR gene possess significant potential as a prognostic marker in OC. Our aim was to comprehensively explore how HRR gene mutations, including but not limited to BRCA, might influence the clinical course","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"5578247"},"PeriodicalIF":1.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-03eCollection Date: 2025-01-01DOI: 10.1155/ogi/8491436
Sara Salihi, Fatma Başak Tanoğlu, Ali Gökçe, Hikmet Tunç Timur, Özge Pasin, Pınar Özcan
Objective: This study evaluated awareness and knowledge of planned oocyte cryopreservation (POC) among Turkish women across diverse sociocultural backgrounds. Design: This is a cross-sectional survey with a 56-item self-administered electronic questionnaire. Setting: Istanbul, Turkiye, June to September 2022. Population: The study evaluated 915 participants between 21 and 45 years. Methods: Women completed a 56-item self-administered online electronic questionnaire survey to identify their demographic information, perspective on family planning, future fertility expectations/plans, oocyte freezing, and degree of knowledge. Main Outcome Measures: Comparison of participants considering and not considering POC. Results: A total of 464 (50.7%) women indicated an intent to undergo POC in the future, with statistically significantly higher university graduates in the group clearly considering POC (p=0.044) and a higher rate of singles indicating an intent to POC. A total of 546 (59.7%) women planned to have children in the future; the participants considered the age of 39.37 (±5.01) as "old" for pregnancy; 748 (81.7%) of the participants thought that the information about age-related fertility decline and POC should be a part of the annual gynecological examination. The level of knowledge about family planning/postponing fertility and POC between the two groups showed that the group considering POC provided significantly more accurate responses to seven items (5th, 6th, 7th, 10th, 11th, 14th, and 17th questions). The group not considering POC answered correctly, "What is the rate of spontaneous female conception?" (p=0.047). Conclusion: The target population expected to benefit from POC in our country had low knowledge and awareness of age-related fertility decline and POC. Most women expected the information to be a part of the annual gynecological examination. The main determinants of the knowledge score and considering POC are education level and relationship status.
{"title":"Evaluation of Women's Awareness and Knowledge of Planned Oocyte Cryopreservation at Different Sociocultural Levels: A Cross-Sectional Survey.","authors":"Sara Salihi, Fatma Başak Tanoğlu, Ali Gökçe, Hikmet Tunç Timur, Özge Pasin, Pınar Özcan","doi":"10.1155/ogi/8491436","DOIUrl":"https://doi.org/10.1155/ogi/8491436","url":null,"abstract":"<p><p><b>Objective:</b> This study evaluated awareness and knowledge of planned oocyte cryopreservation (POC) among Turkish women across diverse sociocultural backgrounds. <b>Design:</b> This is a cross-sectional survey with a 56-item self-administered electronic questionnaire. <b>Setting:</b> Istanbul, Turkiye, June to September 2022. <b>Population:</b> The study evaluated 915 participants between 21 and 45 years. <b>Methods:</b> Women completed a 56-item self-administered online electronic questionnaire survey to identify their demographic information, perspective on family planning, future fertility expectations/plans, oocyte freezing, and degree of knowledge. <b>Main Outcome Measures:</b> Comparison of participants considering and not considering POC. <b>Results:</b> A total of 464 (50.7%) women indicated an intent to undergo POC in the future, with statistically significantly higher university graduates in the group clearly considering POC (<i>p</i>=0.044) and a higher rate of singles indicating an intent to POC. A total of 546 (59.7%) women planned to have children in the future; the participants considered the age of 39.37 (±5.01) as \"old\" for pregnancy; 748 (81.7%) of the participants thought that the information about age-related fertility decline and POC should be a part of the annual gynecological examination. The level of knowledge about family planning/postponing fertility and POC between the two groups showed that the group considering POC provided significantly more accurate responses to seven items (5th, 6th, 7th, 10th, 11th, 14th, and 17th questions). The group not considering POC answered correctly, \"What is the rate of spontaneous female conception?\" (<i>p</i>=0.047). <b>Conclusion:</b> The target population expected to benefit from POC in our country had low knowledge and awareness of age-related fertility decline and POC. Most women expected the information to be a part of the annual gynecological examination. The main determinants of the knowledge score and considering POC are education level and relationship status.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"8491436"},"PeriodicalIF":1.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-28eCollection Date: 2025-01-01DOI: 10.1155/ogi/1866988
Obinna K Nnabuchi, George U Eleje, Joseph I Adinma, Emmanuel O Ugwu, Ahizechukwu C Eke, Joseph I Ikechebelu, Okechukwu C Ikpeze, Betrand O Nwosu, Gerald O Udigwe, Joseph O Ugboaja, Osita S Umeononihu, Chukwudi A Ogabido, Ikechukwu I Mbachu, Chukwuemeka O Ezeama, Richard O Egeonu, Arinze C Ikeotuonye, Tobechi K Njoku, Chukwuemeka C Okoro, Charlotte B Oguejiofor, Ifeanyichukwu J Ofor, Ifeoma M Nnabuchi, Chidinma C Okafor, Chinedu L Olisa, Chigozie G Okafor
Objectives: To determine the effectiveness of perineal massage during the second stage of labour in preventing perineal trauma in nulliparous women. Methods: A randomized control trial involving 104 nulliparous women undergoing vaginal delivery. The participants were randomised into two arms (intervention-group 'A' and control-group 'B') in a 1:1 ratio. The intervention group had perineal massage and routine hands-on technique according to the hospital protocol while the control group received only hands-on technique. The primary outcome measure was the incidence of perineal tears during vaginal delivery, while the secondary outcome measures were the incidence of episiotomy during vaginal delivery, the mean duration of second stage of labour, and perineal pain score. Results: The baseline socio-demographic and maternal characteristics of the participants were similar in both arms. The incidence of perineal lacerations in the intervention group (massage group) was significantly lower than in the control group (27 (54%) vs. 40 (81.6%); p=0.003). Although the incidence of episiotomy (26% vs. 44.9%; RR = 0.66; 95% CI = 0.50-0.88; p=0.060) was not significantly different, mean perineal pain score at 4 h postpartum (4.3 ± 0.3 vs. 6.1 ± 0.50; p=0.03), mean perineal pain score at 24 h postpartum (2.2 ± 0.1 vs. 4.2 ± 0.3; p=0.02), and mean duration of second stage of labour (83.1 ± 17.5 min vs. 94.2 ± 18.9 min; p=0.002) were significantly lower in the intervention-group. There was no significant difference in the neonatal outcomes (head circumference, birth weight, and Apgar scores: p > 0.05) between the two groups. Conclusion: Intrapartum perineal massage significantly decreases the risk of overall perineal trauma, perineal pain, and duration of the second stage of labour among nulliparous parturients during the second stage of labour. Nulliparous women should be counselled on the potential benefits of intrapartum perineal massage, and obstetricians are encouraged to provide the technique to consenting women. Trial Registration: Pan African Clinical Trial Registry (PACTR): PACTR 202207835155214.
目的:探讨产程第二阶段会阴按摩对预防无产妇女会阴创伤的效果。方法:采用随机对照试验,纳入104例阴道分娩的无产妇女。参与者按1:1的比例随机分为两组(干预组“A”和对照组“B”)。干预组按医院方案进行会阴按摩及常规手法治疗,对照组仅进行手法治疗。主要指标是阴道分娩时会阴撕裂的发生率,而次要指标是阴道分娩时会阴切开术的发生率、第二产程的平均持续时间和会阴疼痛评分。结果:两组参与者的基线社会人口统计学和母亲特征相似。干预组(按摩组)会阴撕裂伤发生率明显低于对照组(27例(54%)∶40例(81.6%);p = 0.003)。虽然外阴切开术的发生率(26% vs. 44.9%;rr = 0.66;95% ci = 0.50-0.88;P =0.060)差异无统计学意义,产后4 h会阴疼痛平均评分(4.3±0.3∶6.1±0.50;P =0.03),产后24 h会阴疼痛平均评分(2.2±0.1∶4.2±0.3;P =0.02),第二产程平均持续时间(83.1±17.5 min vs 94.2±18.9 min);P =0.002)显著低于干预组。两组新生儿结局(头围、出生体重、Apgar评分:p < 0.05)无显著差异。结论:产时会阴按摩可显著降低二产程产妇会阴整体创伤、会阴疼痛及二产程持续时间。未产妇女应被告知产时会阴按摩的潜在好处,并鼓励产科医生向同意的妇女提供这项技术。试验注册:泛非临床试验注册中心(PACTR): PACTR 202207835155214。
{"title":"Effectiveness of Intrapartum Perineal Massage in Preventing Perineal Trauma in Nulliparous Women During the Second Stage of Labour: A Randomised Controlled Trial.","authors":"Obinna K Nnabuchi, George U Eleje, Joseph I Adinma, Emmanuel O Ugwu, Ahizechukwu C Eke, Joseph I Ikechebelu, Okechukwu C Ikpeze, Betrand O Nwosu, Gerald O Udigwe, Joseph O Ugboaja, Osita S Umeononihu, Chukwudi A Ogabido, Ikechukwu I Mbachu, Chukwuemeka O Ezeama, Richard O Egeonu, Arinze C Ikeotuonye, Tobechi K Njoku, Chukwuemeka C Okoro, Charlotte B Oguejiofor, Ifeanyichukwu J Ofor, Ifeoma M Nnabuchi, Chidinma C Okafor, Chinedu L Olisa, Chigozie G Okafor","doi":"10.1155/ogi/1866988","DOIUrl":"https://doi.org/10.1155/ogi/1866988","url":null,"abstract":"<p><p><b>Objectives:</b> To determine the effectiveness of perineal massage during the second stage of labour in preventing perineal trauma in nulliparous women. <b>Methods:</b> A randomized control trial involving 104 nulliparous women undergoing vaginal delivery. The participants were randomised into two arms (intervention-group 'A' and control-group 'B') in a 1:1 ratio. The intervention group had perineal massage and routine hands-on technique according to the hospital protocol while the control group received only hands-on technique. The primary outcome measure was the incidence of perineal tears during vaginal delivery, while the secondary outcome measures were the incidence of episiotomy during vaginal delivery, the mean duration of second stage of labour, and perineal pain score. <b>Results:</b> The baseline socio-demographic and maternal characteristics of the participants were similar in both arms. The incidence of perineal lacerations in the intervention group (massage group) was significantly lower than in the control group (27 (54%) vs. 40 (81.6%); <i>p</i>=0.003). Although the incidence of episiotomy (26% vs. 44.9%; RR = 0.66; 95% CI = 0.50-0.88; <i>p</i>=0.060) was not significantly different, mean perineal pain score at 4 h postpartum (4.3 ± 0.3 vs. 6.1 ± 0.50; <i>p</i>=0.03), mean perineal pain score at 24 h postpartum (2.2 ± 0.1 vs. 4.2 ± 0.3; <i>p</i>=0.02), and mean duration of second stage of labour (83.1 ± 17.5 min vs. 94.2 ± 18.9 min; <i>p</i>=0.002) were significantly lower in the intervention-group. There was no significant difference in the neonatal outcomes (head circumference, birth weight, and Apgar scores: <i>p</i> > 0.05) between the two groups. <b>Conclusion:</b> Intrapartum perineal massage significantly decreases the risk of overall perineal trauma, perineal pain, and duration of the second stage of labour among nulliparous parturients during the second stage of labour. Nulliparous women should be counselled on the potential benefits of intrapartum perineal massage, and obstetricians are encouraged to provide the technique to consenting women. <b>Trial Registration:</b> Pan African Clinical Trial Registry (PACTR): PACTR 202207835155214.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"1866988"},"PeriodicalIF":1.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-08eCollection Date: 2025-01-01DOI: 10.1155/ogi/8899358
Mario Arturo González Mariño
Objective: To describe the incidence of hydatidiform mole in Colombia. Design: Cross-sectional descriptive study. Setting: Colombia. Population or Sample: The total population at risk of hydatidiform mole (15-49 years old) from 2015 to 2023 was 117.890.729 women. Methods: A search of the national database of the Ministry of Health and Social Protection of Colombia using ICD-10 for hydatidiform mole and ectopic pregnancy was conducted from 2015 to 2023. Incidences were calculated using data from the National Department of Statistics of Colombia. Main Outcome Measures: The incidence of hydatidiform mole was calculated by ratios compared with the live births, the proportion of pregnancies, and the incidence rate in the at-risk population. Results: In the reviewed period, 2247 cases of hydatidiform mole were reported. The proportion of unspecified hydatidiform moles during the evaluation period was 78.59% of the reports, the incidence ratio was one hydatidiform mole for every 2486 live births, the proportion was 37.7 × 105 pregnancies and the cumulative incidence was 1.90 × 105 women of 15-49 years. The age range with the highest number of cases was 20-29 years with 1039 cases. Conclusions: The high proportion of unspecified hydatidiform mole far exceeds the diagnoses of complete and partial hydatidiform mole. The descriptive design of the study does not allow us to determine the causes of these results. Future studies with more complex methodological designs are required to explain these findings.
{"title":"A Cross-Sectional Analysis of the Incidence of Hydatidiform Mole in Colombia.","authors":"Mario Arturo González Mariño","doi":"10.1155/ogi/8899358","DOIUrl":"10.1155/ogi/8899358","url":null,"abstract":"<p><p><b>Objective:</b> To describe the incidence of hydatidiform mole in Colombia. <b>Design:</b> Cross-sectional descriptive study. <b>Setting:</b> Colombia. <b>Population or Sample:</b> The total population at risk of hydatidiform mole (15-49 years old) from 2015 to 2023 was 117.890.729 women. <b>Methods:</b> A search of the national database of the Ministry of Health and Social Protection of Colombia using ICD-10 for hydatidiform mole and ectopic pregnancy was conducted from 2015 to 2023. Incidences were calculated using data from the National Department of Statistics of Colombia. <b>Main Outcome Measures:</b> The incidence of hydatidiform mole was calculated by ratios compared with the live births, the proportion of pregnancies, and the incidence rate in the at-risk population. <b>Results:</b> In the reviewed period, 2247 cases of hydatidiform mole were reported. The proportion of unspecified hydatidiform moles during the evaluation period was 78.59% of the reports, the incidence ratio was one hydatidiform mole for every 2486 live births, the proportion was 37.7 × 10<sup>5</sup> pregnancies and the cumulative incidence was 1.90 × 10<sup>5</sup> women of 15-49 years. The age range with the highest number of cases was 20-29 years with 1039 cases. <b>Conclusions:</b> The high proportion of unspecified hydatidiform mole far exceeds the diagnoses of complete and partial hydatidiform mole. The descriptive design of the study does not allow us to determine the causes of these results. Future studies with more complex methodological designs are required to explain these findings.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"8899358"},"PeriodicalIF":1.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-05eCollection Date: 2025-01-01DOI: 10.1155/ogi/4044738
Omar Sadek, Nora Fahim, Hana Yehia, Mariam Elmashad, Farah Alaa, Abdulrahman Rakha, Ahmad Khaled, Nadine Sherif
Objective: This study aims to determine the incidence of episiotomy in Kasr Alainy OBGYN Hospital in Cairo, Egypt. The objectives include identifying and examining the reasons behind the notably higher episiotomy rates in this region, and assessing the relevance of general WHO recommendations in lower-middle-income countries. Design: This observational cross-sectional study was conducted between March 1, 2022 and June 30, 2022, to determine the incidence of episiotomy among vaginal deliveries in the hospital. Setting: Data was collected from patient charts at Kasr Alainy OBGYN Hospital in Cairo, Egypt. Patient Sample: The total number of patient charts inspected was 1731, of which 1545 met the inclusion criteria. Methods: Data were manually collected from patient hospital records at the end of each day, and entered into a standardized data-collection form. The data collected was then statistically analyzed using SPSS. Main Outcome Measures: The overall incidence of episiotomy was 64%. Results: When analyzed by gravidity, the incidence was found to be 97% in primigravida patients and 52% in multigravida patients. Additionally, several other associated factors were examined. Conclusions: The incidence of episiotomy at Kasr Alainy OBGYN Hospital surpasses the rate recommended by the WHO. Our observations suggest that the primary contributing factors to this elevated incidence include perineal rigidity, the duration of labor, and local practice standards. Further research is recommended to explore the impact of perineal massage before and during delivery, as well as patients' lifestyle factors, on the necessity for episiotomy.
{"title":"Incidence of Episiotomy in Kasr Alainy OBGYN Hospital in Cairo, Egypt: A Cross-Sectional Study.","authors":"Omar Sadek, Nora Fahim, Hana Yehia, Mariam Elmashad, Farah Alaa, Abdulrahman Rakha, Ahmad Khaled, Nadine Sherif","doi":"10.1155/ogi/4044738","DOIUrl":"10.1155/ogi/4044738","url":null,"abstract":"<p><p><b>Objective:</b> This study aims to determine the incidence of episiotomy in Kasr Alainy OBGYN Hospital in Cairo, Egypt. The objectives include identifying and examining the reasons behind the notably higher episiotomy rates in this region, and assessing the relevance of general WHO recommendations in lower-middle-income countries. <b>Design:</b> This observational cross-sectional study was conducted between March 1, 2022 and June 30, 2022, to determine the incidence of episiotomy among vaginal deliveries in the hospital. <b>Setting:</b> Data was collected from patient charts at Kasr Alainy OBGYN Hospital in Cairo, Egypt. <b>Patient Sample:</b> The total number of patient charts inspected was 1731, of which 1545 met the inclusion criteria. <b>Methods:</b> Data were manually collected from patient hospital records at the end of each day, and entered into a standardized data-collection form. The data collected was then statistically analyzed using SPSS. <b>Main Outcome Measures:</b> The overall incidence of episiotomy was 64%. <b>Results:</b> When analyzed by gravidity, the incidence was found to be 97% in primigravida patients and 52% in multigravida patients. Additionally, several other associated factors were examined. <b>Conclusions:</b> The incidence of episiotomy at Kasr Alainy OBGYN Hospital surpasses the rate recommended by the WHO. Our observations suggest that the primary contributing factors to this elevated incidence include perineal rigidity, the duration of labor, and local practice standards. Further research is recommended to explore the impact of perineal massage before and during delivery, as well as patients' lifestyle factors, on the necessity for episiotomy.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"4044738"},"PeriodicalIF":1.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11824849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-16eCollection Date: 2025-01-01DOI: 10.1155/ogi/1706041
Nour Khalil, Nadine El Kassis, Malak Moubarak, Christian Chaccour, Samer Maalouf, Elie Nemr, Houssein El Hajj, Maroun Moukarzel, David Atallah
Background: Pelvic organ prolapse (POP) is a benign condition that can adversely affect women's quality of life. Mesh sacrocolpopexy is an effective surgical treatment for POP, but is considered a complex and risky surgery for obese and elderly women. The objective of this study was to assess the impact of age and obesity on the outcomes of minimally invasive sacrocolpopexy. Methods: We performed a retrospective cohort study reviewing all minimally invasive sacrocolpopexy cases performed between 2003 and 2021. Data on operative time, hospital stay, conversion rate, perioperative injuries, early and late postoperative complications were collected. Surgical success was evaluated by gynecological examination at each follow-up visit. Results: One hundred seventy subjects were included, of whom 44% were older than 65 years and 58% had a body mass index (BMI) above 25 kg/m2. Seventy percent presented stage III uterovaginal prolapse. All patients achieved a good subjective outcome with no reported prolapse with a mean follow-up of 6 years. The rate of de novo stress urinary incontinence was 3.2%. Vaginal implant exposure was found in 4% of cases. A bivariate analysis studying the impact of older age (≥ 65 vs. < 65 years) and higher BMI (≥ 25 vs. < 25) on surgical and postoperative outcomes did not show any significant differences between the subgroups (p > 0.05). Conclusion: In experienced hands, laparoscopic sacrocolpopexy can be used as a safe and effective procedure for operable patients with POP, even when patients are between 65 and 80 years or have a BMI of 25 kg/m2 and above.
{"title":"Impact of Age and Body Mass Index on the Outcomes of Laparoscopic Mesh Sacrocolpopexy.","authors":"Nour Khalil, Nadine El Kassis, Malak Moubarak, Christian Chaccour, Samer Maalouf, Elie Nemr, Houssein El Hajj, Maroun Moukarzel, David Atallah","doi":"10.1155/ogi/1706041","DOIUrl":"10.1155/ogi/1706041","url":null,"abstract":"<p><p><b>Background:</b> Pelvic organ prolapse (POP) is a benign condition that can adversely affect women's quality of life. Mesh sacrocolpopexy is an effective surgical treatment for POP, but is considered a complex and risky surgery for obese and elderly women. The objective of this study was to assess the impact of age and obesity on the outcomes of minimally invasive sacrocolpopexy. <b>Methods:</b> We performed a retrospective cohort study reviewing all minimally invasive sacrocolpopexy cases performed between 2003 and 2021. Data on operative time, hospital stay, conversion rate, perioperative injuries, early and late postoperative complications were collected. Surgical success was evaluated by gynecological examination at each follow-up visit. <b>Results:</b> One hundred seventy subjects were included, of whom 44% were older than 65 years and 58% had a body mass index (BMI) above 25 kg/m<sup>2</sup>. Seventy percent presented stage III uterovaginal prolapse. All patients achieved a good subjective outcome with no reported prolapse with a mean follow-up of 6 years. The rate of de novo stress urinary incontinence was 3.2%. Vaginal implant exposure was found in 4% of cases. A bivariate analysis studying the impact of older age (≥ 65 vs. < 65 years) and higher BMI (≥ 25 vs. < 25) on surgical and postoperative outcomes did not show any significant differences between the subgroups (<i>p</i> > 0.05). <b>Conclusion:</b> In experienced hands, laparoscopic sacrocolpopexy can be used as a safe and effective procedure for operable patients with POP, even when patients are between 65 and 80 years or have a BMI of 25 kg/m<sup>2</sup> and above.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2025 ","pages":"1706041"},"PeriodicalIF":1.6,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Platelet-rich plasma (PRP) promotes the wound-healing process and reduces pain. Cord blood platelet-rich plasma (CB-PRP), which can be easily collected from the umbilical cord and reapplied to a cesarean section wound, has been proposed to have similar effects as PRP. This paper hypothesizes that CB-PRB would provide beneficial effects in terms of wound healing and pain reduction in women undergoing cesarean section. This study is a randomized controlled trial involving 52 pregnant women who underwent cesarean sections. Participants were assigned to either the intervention group (n = 26) or the control group (n = 26) at the Obstetrics and Gynecology Clinic of Police General Hospital. Cord blood PRP was applied to the subcutaneous layer and the surgical wound immediately following the cesarean section. The efficacy of wound healing was evaluated using the REEDA scale score on days 1 and 3 postoperatively, and the Vancouver Scar Scale (VSS) was assessed in the 8th week postoperation. The efficacy in reducing pain was measured using a Visual Analog Scale on days 1 and 3 postoperatively. The mean REEDA scale on day 1 (mean ± SD: 1.5 ± 0.2561.5 ± 0.256 in the CB-PRP group and 2.5 ± 0.267 in the control group; p=0.009) and the mean VSS score at the 8th week (mean ± SD: 2.577 ± 2.003 in the CB-PRP group and 6.962 ± 2.441 in the control group; p < 0.001) were significantly lower in the CB-PRP group than those in the control group. However, there were no differences in Visual Analog Scale values between the two groups. The findings indicate that CB-PRP potentially promotes wound healing following cesarean sections but does not reduce pain. Further research is needed to confirm the beneficial effects of CB-PRP.
{"title":"Cord Blood Platelet-Rich Plasma in Cesarean Section Wound Management.","authors":"Amornrat Thanachaiviwat, Sutham Suthaporn, Patana Teng-Umnuay","doi":"10.1155/ogi/4155779","DOIUrl":"10.1155/ogi/4155779","url":null,"abstract":"<p><p>Platelet-rich plasma (PRP) promotes the wound-healing process and reduces pain. Cord blood platelet-rich plasma (CB-PRP), which can be easily collected from the umbilical cord and reapplied to a cesarean section wound, has been proposed to have similar effects as PRP. This paper hypothesizes that CB-PRB would provide beneficial effects in terms of wound healing and pain reduction in women undergoing cesarean section. This study is a randomized controlled trial involving 52 pregnant women who underwent cesarean sections. Participants were assigned to either the intervention group (<i>n</i> = 26) or the control group (<i>n</i> = 26) at the Obstetrics and Gynecology Clinic of Police General Hospital. Cord blood PRP was applied to the subcutaneous layer and the surgical wound immediately following the cesarean section. The efficacy of wound healing was evaluated using the REEDA scale score on days 1 and 3 postoperatively, and the Vancouver Scar Scale (VSS) was assessed in the 8th week postoperation. The efficacy in reducing pain was measured using a Visual Analog Scale on days 1 and 3 postoperatively. The mean REEDA scale on day 1 (mean ± SD: 1.5 ± 0.2561.5 ± 0.256 in the CB-PRP group and 2.5 ± 0.267 in the control group; <i>p</i>=0.009) and the mean VSS score at the 8th week (mean ± SD: 2.577 ± 2.003 in the CB-PRP group and 6.962 ± 2.441 in the control group; <i>p</i> < 0.001) were significantly lower in the CB-PRP group than those in the control group. However, there were no differences in Visual Analog Scale values between the two groups. The findings indicate that CB-PRP potentially promotes wound healing following cesarean sections but does not reduce pain. Further research is needed to confirm the beneficial effects of CB-PRP.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2024 ","pages":"4155779"},"PeriodicalIF":1.6,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}